CLINICAL OUTCOMES: CHRONIC PAIN Targeted Drug Delivery

STUDIES CONFIRM EFFECTIVENESS

Pain Relief

  • Significant improvement in back and leg pain at 6 and 12 months (p < 0.001) compared to baseline1
  • 60% mean pain relief after 6 months2

Improved Function and Quality of Life

  • 87% of patients rated their quality of life as fair to excellent1
  • 74% of patients reported increased activity levels2
  • 66% of patients successfully reduced their disability at 12 months1

Patient Satisfaction and Reduction in Oral Medication

  • 88% of patients were satisfied with intrathecal therapy2
  • 90% of patients would recommend therapy to a family member or friend1
  • Significant reduction in oral medication intake (p < 0.0001)2

More Cost-effective Than Conventional Treatments

  • Evidence suggests that the cumulative future costs of intrathecal drug delivery may be less compared to conventional medical management (CMM).3,4
  • In one study, the lifetime cost analysis indicated savings of $3,111 per patient per year for TDD compared to CMM.4
    • The lifetime financial benefit of TDD was attributed to: lower inpatient facility costs, reduced prescription expenses, as well as fewer ER visits, ambulatory surgeries, office visits, and adjunctive therapies.

1

Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain; report from the National Outcomes Registry for Low Back Pain. Pain Med. 2004;5(1):6-13.

2

Roberts LJ, Finch PM, Goucke CR, Price LM. Outcome of intrathecal opioids in chronic noncancer pain. Eur J Pain. 2001;5(4):353-361.

3

Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg. 2002;97(4):803-810.

4

Guillemette S, Witzke S, Leier J, Hinnenthal J, Prager JP. Medical cost impact of intrathecal drug delivery for noncancer pain. Pain Medicine. 2013;14:504-515.